Study identification

EU PAS number

EUPAS46882

Study ID

47631

Official title and acronym

APPRECIATE™ (APREmilast ClinIcAl Treatment Experience in psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated with Apremilast in Clinical Dermatology Practice.(20200066 / CC-10004-PSOR-013)

DARWIN EU® study

No

Study countries

Austria
Croatia
Czechia
Germany
Ireland
Slovenia
Spain
Sweden
Switzerland
United Kingdom

Study description

This is a retrospective, multi-center observational cohort study. This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed by a selected number of countries in Europe, depending on apremilast local availability. The design of this apremilast retrospective study aims to provide clinical information regarding the treatment initiation and outcomes in psoriasis patients when prescribed apremilast in real world settings. In addition, this study is aiming at capturing physicians' and patients' treatment goals when initiating apremilast and whether these goals are achieved following apremilast use. This study is primarily descriptive in nature, and no a priori hypotheses are specified. Patients must voluntarily sign an informed consent form, be 18 or over, have been diagnosed with plaque psoriasis and have been treated with apremilast during the previous 5-7 months to participate in this study. They must not be involved in any other clinical study involving apremilast.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution
Multiple centres: 133 centres are involved in the study

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable